Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO)
09 juil. 2021 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
Surrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043
25 juin 2021 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications
17 juin 2021 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
Surrozen Publishes Article in Nature Communications Demonstrating Selective Wnt Mimetics Stimulate Bone Mass Accrual in Disease Models of Osteoporosis, Aging and Long-Bone Fracture
01 juin 2021 08h00 HE
|
Surrozen, Inc.
Results Demonstrate Rapid and Robust Bone-building Effects from Selective Wnt Agonists in Proof of Concept, Preclinical Studies of Wnt Mimetics for the Treatment of Diseases of Low Bone Mineral...
Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043, in Six Oral and Poster Presentations at 2021 Digestive Disease Week Conference
24 mai 2021 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
Surrozen Strengthens Board of Directors with Appointments of Mace Rothenberg, M.D., and Christopher Chai
06 mai 2021 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
Surrozen Expands Board of Directors with Appointment of Mary Haak-Frendscho, Ph.D.
11 mars 2021 14h37 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
Surrozen Expands Board of Directors with Appointment of Shao-Lee Lin, M.D., Ph.D.
02 févr. 2021 18h31 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
Surrozen to Present at the Stifel 2020 Virtual Healthcare Conference
12 nov. 2020 07h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker,...
Surrozen Appoints Charles Williams as Chief Financial Officer
29 oct. 2020 07h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the appointment of...